In fact, TKI-targeted therapy induces megakaryocytic differentiation in human CML cells, which might be partially attributed to the induction of MPL expression, a crucial cytokine receptor in megakaryocytic fate determination10–12. Here, MPL is linked to chronic myelogenous leukemia, BCR-ABL1 positive.